Table 1.

Treatment-emergent CV AEs in carfilzomib-treated patients across RRMM trials (N = 2044)

	Any-grade AEs	Grade ≥3 AEs	Serious-grade AEs
Cardiac failure	137 (6.7)	90 (4.4)	79 (3.9)
Cardiac failure congestive	51 (2.5)	36 (1.8)	34 (1.7)
Cardiac failure	38 (1.9)	20 (1.0)	19 (0.9)
Pulmonary edema	31 (1.5)	19 (0.9)	17 (0.8)
Ejection fraction decreased	16 (0.8)	6 (0.3)	0
Cardiac failure acute	7 (0.3)	5 (0.2)	4 (0.2)
Acute pulmonary edema	6 (0.3)	6 (0.3)	5 (0.2)
RV failure	3 (0.1)	3 (0.1)	2 (<0.1)
Acute left ventricular failure	2 (<0.1)	1 (<0.1)	2 (<0.1)
Cardiopulmonary failure	2 (<0.1)	1 (<0.1)	1 (<0.1)
Hepatic congestion	2 (<0.1)	2 (<0.1)	0
Cardiac failure chronic	1 (<0.1)	1 (<0.1)	0
Cardiogenic shock	1 (<0.1)	1 (<0.1)	0
Hepatojugular reflux	1 (<0.1)	0	0
Hypertension	378 (18.5)	120 (5.9)	13 (0.6)
Dyspnea	653 (31.9)	92 (4.5)	48 (2.3)
Ischemic heart disease	75 (3.7)	40 (2.0)	36 (1.8)

Pooled analysis is from the phase 1 trials (PX-171-001, PX-171-002, PX-171-006, PX-171-008), the phase 2 trials (PX-171-003-A0, PX-171-003-A1, PX-171-004, PX-171-005, and 2011-002), and the phase 3 ASPIRE (PX-171-009), ENDEAVOR (2011-003), and FOCUS trials (PX-171-011). All data are n (%). Cardiac failure and hypertension events are listed as standardized MedDRA query, narrow scope, and ischemic heart disease event is listed as standardized MedDRA query, broad scope.